![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/7/7d/Rapastinel.svg/640px-Rapastinel.svg.png&w=640&q=50)
Rapastinel
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Rapastinel?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Rapastinel (INNTooltip International Nonproprietary Name) (former developmental code name GLYX-13) is a novel antidepressant that was under development by Allergan (previously Naurex) as an adjunctive therapy for the treatment of treatment-resistant depression.[1][2] It is a centrally active, intravenously administered (non-orally active) amidated tetrapeptide that acts as a novel and selective modulator of the NMDA receptor.[1][2][3] The drug is a rapid-acting and long-lasting antidepressant as well as robust cognitive enhancer by virtue of its ability to enhance NMDA receptor-mediated signal transduction and synaptic plasticity.[1][2][3]
Quick Facts Clinical data, Other names ...
![]() | |
![]() | |
Clinical data | |
---|---|
Other names | GLYX-13; BV-102 |
Routes of administration | Intravenous |
Drug class | Selective NMDA receptor modulator |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H31N5O6 |
Molar mass | 413.475 g·mol−1 |
3D model (JSmol) | |
| |
|
Close